Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and ...

Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseasesInitial data for NKX019 in multiple autoimm ...

NKX019 is an allogeneic, off-the-shelf, chimeric antigen receptor (CAR) NK-cell therapy candidate engineered to deplete CD19-positive cells in B-cell mediated autoimmune disease. The approach ...

Corticosteroids inhibit antigen presentation, cytokine production, and proliferation of lymphocytes. Corticosteroids have a profound effect on the concentration of peripheral blood leukocytes.

Therapeutic tolerogenic antigen-presenting cells can be generated in vivo by delivering, via lipid nanoparticles, mRNA coding for the inhibitory protein programmed death ligand 1, as shown in ...

Immunotherapy is the treatment of disease by inducing, enhancing or suppressing an immune response. Activation immunotherapies induce or amplify an immune response and are used in vaccines and as ...